v3.26.1
BALANCE SHEET - USD ($)
Mar. 31, 2026
Dec. 31, 2025
Jun. 30, 2025
Jun. 30, 2024
Current Liabilities        
Accrued expenses $ 590 $ 590    
Amount due to related party 10,000    
Total Current Liabilities 10,590 590    
Total Liabilities 10,590 590    
Shareholders’ Deficit        
Ordinary shares    
Additional paid-in capital 100 100    
Accumulated deficit (10,590) (590)    
Subscription receivable (100) (100)    
Total Shareholders’ Deficit (10,590) (590)    
Total Liabilities and Shareholders’ Deficit    
D. Boral ARC Acquisition I Corp [Member]        
Current Assets        
Cash and cash equivalents 243,576 420,340    
Prepaid expenses 156,259 203,134    
Total Current Assets 399,835 623,474    
Non-Current Assets        
Cash held in trust account 287,319,687 284,776,628    
Total Assets 287,719,522 285,400,102    
Current Liabilities        
Accrued expenses 345,713 37,611    
Total Current Liabilities 345,713 37,611    
Total Liabilities 345,713 37,611    
Class A ordinary shares subject to possible redemption, $0.0001 par value; 500,000,000 shares authorized; 28,000,000 shares issued and outstanding, at redemption value of $10.26 on March 31, 2026 and $10.17 on December 31, 2025, respectively 287,319,687 284,776,628    
Shareholders’ Deficit        
Preferred shares, $0.0001 par value; 5,000,000 shares authorized; none issued and outstanding    
Additional paid-in capital    
Accumulated deficit 52,802 584,543    
Total Shareholders’ Deficit 54,122 585,863    
Total Liabilities and Shareholders’ Deficit 287,719,522 285,400,102    
D. Boral ARC Acquisition I Corp [Member] | Class A Ordinary Shares [Member]        
Shareholders’ Deficit        
Ordinary shares 120 120    
D. Boral ARC Acquisition I Corp [Member] | Class B Ordinary Shares [Member]        
Shareholders’ Deficit        
Ordinary shares [1] 1,200 1,200    
Exascale Labs Inc. [Member]        
Current Assets        
Cash and cash equivalents 984,830   $ 4,231,689 $ 969,626
U.S. Dollar Coin 4,074,415    
Accounts receivable, net 1,830,105   152,536 123,332
Prepaid research and development expenses 625,000    
Advance to suppliers 106,801   1,030,761 280,497
Refundable deposits receivable 510,000   681,125 110,000
Other receivables   1,207,626 2,884,694
Total Current Assets 8,131,151   7,303,737 4,368,149
Non-Current Assets        
Deferred offering costs 95,000   (0)  
Equipment, net 14,406   19,600 23,696
Total Non-Current Assets 109,406   19,600 23,696
Total Assets 8,240,557   7,323,337 4,391,845
Current Liabilities        
Accounts payable 743,742   90,015 128,040
Simple agreements for future equity 26,842,205   18,243,885 9,321,564
Contract liabilities 109,657   432,760 95,326
Refundable deposits payable 1,174,702   1,445,580 223,205
Other current liabilities 283,612   107,481 113,693
Total Current Liabilities 29,153,918   20,319,721 9,881,828
Total Liabilities 29,153,918   20,319,721 9,881,828
Shareholders’ Deficit        
Ordinary shares   15 15
Additional paid-in capital 220,636   220,636 67,370
Accumulated deficit (21,134,012)   (13,217,035) (5,557,368)
Total Shareholders’ Deficit (20,913,361) $ (18,280,930) (12,996,384) (5,489,983)
Total Liabilities and Shareholders’ Deficit 8,240,557   7,323,337 $ 4,391,845
Exascale Labs Inc. [Member] | Class A Ordinary Shares [Member]        
Shareholders’ Deficit        
Ordinary shares 3    
Exascale Labs Inc. [Member] | Class B Ordinary Shares [Member]        
Shareholders’ Deficit        
Ordinary shares $ 12    
[1] Includes an aggregate of 321,429 Ordinary Shares cancelled on September 9, 2025 to the extent that the underwriters’ over-allotment was not exercised.